Alivus Life Sciences has the GF Score of 85, which implies that the company
might have
Good outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Alivus Life Sciences
might have
Good outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Alivus Life Sciences (NSE:ALIVUS) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Alivus Life Sciences GF Score Related Terms
NSE:ALIVUS vs ZTS, UTHR: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's GF Score distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's GF Score falls into.
Alivus Life Sciences (NSE:ALIVUS) has a GF Score of 85 as of Jul. 11, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Alivus Life Sciences and its competitors. This is 93% above median its historical median of 44.00. Over the past decade, Alivus Life Sciences' GF Score has ranged from 21.00 to 89.00.
Is Alivus Life Sciences' GF Score too high?
Alivus Life Sciences' current GF Score of 85 is 93% above median its 10-year median of 44.00. Over the past 10 years, this metric has ranged from a low of 21.00 to a high of 89.00. Overall, Alivus Life Sciences has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' GF Score compare to ZTS and UTHR?
Alivus Life Sciences' GF Score of 85 can be compared against companies in the Drug Manufacturers industry. Historically, Alivus Life Sciences' own GF Score has ranged from 21.00 to 89.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Alivus Life Sciences and its competitors. Alivus Life Sciences's current GF Score is 85, which is 93% above median its own 10-year median of 44.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,007.58, compared to a current price of ₹1,160.10 — trading 15.1% above its estimated fair value. The current GF Score is 85, which is 93% above median its 10-year median of 44.00. Alivus Life Sciences' overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current GF Score is 85 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,160.10 is trading 15.1% above its estimated GF Value™ of ₹1,007.58.
GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:ALIVUS:
GF Score: 85 (93% above median its 10-year median of 44.00)
GF Value™: ₹1,007.58 vs. price of ₹1,160.10 (15.1% above fair value)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
85GF Score
Get the complete analysis for NSE:ALIVUS
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 